Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
45.17
+0.32 (0.71%)
Feb 24, 2026, 4:00 PM EST - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 6 analysts that cover Collegium Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $51.17, which forecasts a 13.28% increase in the stock price over the next year. The lowest target is $37 and the highest is $60.
Price Target: $51.17 (+13.28%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $58 → $56 | Buy | Maintains | $58 → $56 | +23.98% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 → $60 | Strong Buy | Reiterates | $46 → $60 | +32.83% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $48 → $56 | Strong Buy | Maintains | $48 → $56 | +23.98% | Jan 8, 2026 |
| Barclays | Barclays | Buy Initiates $58 | Buy | Initiates | $58 | +28.40% | Dec 9, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $45 → $48 | Strong Buy | Maintains | $45 → $48 | +6.27% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
796.86M
from 631.45M
Increased by 26.20%
Revenue Next Year
825.05M
from 796.86M
Increased by 3.54%
EPS This Year
7.62
from 1.86
Increased by 310.30%
EPS Next Year
8.10
from 7.62
Increased by 6.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 824.0M | 868.4M | ||||
| Avg | 796.9M | 825.1M | ||||
| Low | 763.8M | 761.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 30.5% | 9.0% | ||||
| Avg | 26.2% | 3.5% | ||||
| Low | 21.0% | -4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7.98 | 10.59 | ||||
| Avg | 7.62 | 8.10 | ||||
| Low | 7.10 | 6.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 329.8% | 39.0% | ||||
| Avg | 310.3% | 6.4% | ||||
| Low | 282.3% | -9.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.